Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 33.6591
- Book/Share -1.4667
- PB -151.3309
- Debt/Equity -26.0193
- CurrentRatio 0.7245
- ROIC 0.0902
- MktCap 398773949400.0
- FreeCF/Share 11.6078
- PFCF 19.3871
- PE 167.4273
- Debt/Assets 0.5134
- DivYield 0.0295
- ROE 4.975
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 8, 2026 |
| Resumed | ABBV | UBS | -- | Neutral | -- | $240 | Jan. 7, 2026 |
| Upgrade | ABBV | HSBC Securities | Hold | Buy | -- | $265 | Dec. 10, 2025 |
| Initiation | ABBV | Scotiabank | -- | Sector Outperform | -- | $280 | Nov. 13, 2025 |
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
News
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Negative
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 adjusted EPS guidance of $14.37–$14.57 excludes unpredictable IPR&D and milestone costs, raising concerns about reliance on M&A for future growth.
Read More
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
Read More
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
Read More
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.16 per share a year ago.
Read More
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
Published: February 03, 2026 by: PRNewsWire
Sentiment: Neutral
The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences. Natrelle® champions women's voices to provide support at every step of their breast aesthetics journey.
Read More
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.
Read More
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
10 Highest Rated Dividend Kings For Generations Of Income
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
Read More
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is the Options Market Predicting a Spike in AbbVie Stock?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ABBV stock based on the movements in the options market lately.
Read More
The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
Published: January 27, 2026 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premier health care incubator and innovation hub, announced today a call for applications for the 2026 AbbVie Foundation Health Equity Accelerator. Now in its second year, the accelerator provides resources and coaching to select nonprofit organizations to advance their innovative solutions that expand a.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
Read More
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Read More
AbbVie plans to build out its presence in obesity market
Published: January 14, 2026 by: Reuters
Sentiment: Positive
AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra.
Read More
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.
Read More
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.
Read More
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.
Read More
AbbVie: The Dividend Does Not Lie
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Current valuation appears stretched, with ABBV stock trading at 23.5x P/E and a PEGY ratio of 1.41x.
Read More
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
Published: January 07, 2026 by: Reuters
Sentiment: Positive
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Read More
AbbVie Near Deal for Revolution Medicines
Published: January 07, 2026 by: WSJ
Sentiment: Positive
The cancer-drug biotech firm has a market value around $16 billion.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
What Can Trigger A Breakout In Abbvie Stock?
Published: January 06, 2026 by: Forbes
Sentiment: Positive
AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpassing 30% within comparable periods, including significant years such as 2017 and 2024.
Read More
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
Read More
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael
- Employees 55000